Tag: VIVA 2025
‘Excellent’ one-year outcomes from ROADSTER 3 show TCAR is ‘safe and...
One-year outcomes in the ROADSTER 3 post-approval study to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) using the Enroute stent and...
PERFORMANCE III demonstrates “very low” 30-day event rates for dual neuroprotection...
Thirty-day results from the PERFORMANCE III study of integrated embolic protection (IEP) in transcarotid artery revascularisation (TCAR) demonstrate "very low" 30-day event rates. Sean...
